Pyxis Oncology’s IPO raised $168 million as the biotech steers toward the clinic with drug candidates and technology licensed from Pfizer. Theseus Pharma, IsoPlexis, and Cognition Therapeutics also went public; combined the four companies raised nearly half a billion dollars.
It has a patent-pending “biochip” technology that analyzes and “fingerprints” single cells, studying their immune response: That is, the excretion of a number of proteins like cytokines, chemokines and growth factors.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
IsoPlexis, a Yale spinout developing an immunologic assay that helps researchers understand how therapies impact individual patients on a cellular level, seems to have raised a nice chunk of startup capital. The company, formed last year by a couple of MBA candidates, has raised $1.3 million of a $1.7 million early-stage round, according to a […]